1. Frimodt-Møller N. Fusidic acid (fusidate sodium). In: Grayson ML, Kucers A, Crowe SM, et al, eds. Kucers’ Te Use of Antibiotics. 6th ed. London: CRC Press; 2010: 945-954.
2. Collignon P, Turnidge J. Fusidic acid in vitro activity. Int J Antimicrob Agents. 1999;12(suppl 2):45-58.
3. Drugeon HB, Caillon J, Juvin ME. In-vitro antibacterial activity of fusidic acid alone and in combination with other antibiotics against methicillin-sensitive and resistant Staphylococcus
aureus. J Antimicrob Chemother. 1994; 34:899-907.Verbist L. THe antimicrobial activity of fusidic acid. J Antimicrob Chemother. 1990;25(suppl B):1-5.
4. Mandell GL. Fusidic acid. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 7th ed. Churchill Livingstone; 2010:356.
5. Jones RN, Mendes RE, Sader HS, Castanheira M. In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United
States. Clin Infect Dis. 2011;52(suppl 7): 477-486.
6. Frimont-Moller N. Fusidic Acid. In: Kucers’ the use of antibiotics (Ed. Grayson ML). 6th ed, 2010, Hodder Arnold an hachette UK Company, London: p 945-954.
7. Falagas ME, Kopterides P. Old antibiotics for infections in critically ill patients. Curr Opin Crit Care 2007; 13: 592-597.
8. Farrell DJ, Castanheira M, Chopra I. Characterization of global patterns and the genetics of fusidic acid resistance. Clin Infect Dis. 2011;52(suppl 7):487-492.
9. Still JG, Clark K, Degenhardt TP, et al. Pharmacokinetics and safety of single, multiple and loading doses of fusidic acid in health subjects. Clin Infect Dis. 2011;52(suppl 7): 504-512.
10. Cowan R, Johnson PDR, Urbancic K, Grayson ML. A timely reminder about the concomitant use of fusidic acid with statins. Clin Infect Dis. 2013;57:329-330.
11. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect
Dis. 2004; 38: 521-528.
12. Livermore D, James D, Duckworth G, Stephens P. Fusidic acid use and resistance. Lancet. 2002; 360: 806. 102.
13. Brown EM, Tomas P. Fusidic acid resistance in Staphylococcus aureus isolates. Lancet. 2002; 359: 803.
14. Turnidge J. Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. Int J of Antimicrobial Agents. 1999;12(suppl 2):23-34.
15. Godtfredsen WO, Jahnsen S, Lorck H, et al. Fusidic acid: a new antibiotic. Nature. 1962;193:987.
16. Castanheira M, Watters AA, Bell JM, et al. Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007-
2008. Antimicrob Agents Chemother. 2010; 54:3614-3617.
17. O’Neill AJ, Larsen AR, Skov R, et al. Characterization of epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus. J Clin Microbiol. 2007;45: 1505-1510.
18. Jones RN, Castanheira M, Rhomberg PR, et al. Performance of fusidic acid (CEM-102) susceptibility testing reagents: broth microdilution, disk difusion, and Etest methods as applied to
Staphylococcus aureus. J Clin Microbiol. 2010;48:972-976.
19. Howden BP, Grayson ML. Dumb and dumber—the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis. 2006;42:394-
400.
20. Turnidge J, Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents. 1999;12(suppl 2):35-44.
21. McLaws F, Chopra I, O’Neill AJ. High prevalence of resistance to fusidic acid in clinical isolates of Staphylococcus epidermidis. J Antimicrob Chemother. 2008;61:1040-1043.
22. Castanheira M, Watters AA, Mendes RE, et al. Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphyloccus spp. from European countries (2008). J
Antimicrob Chemother. 2010;65: 1353-1358.
23. Coombs GW, Nimmo GR, Bell JM, et al; Australian Group for Antimicrobial Resistance. Genetic diversity among community methicillin-resistant Staphylococcus aureus strains causing
outpatient infections in Australia. Australian Group of Antimicrobial Resistance. J Clin Microbiol. 2004;42:4735-4743.
24. MacGowan AP, Greig MA, Andrews JM, et al. Pharmacokinetics and tolerance of a new flm-coated tablet of sodium fusidate administered as a single oral dose to health volunteers. J Anti-
microb Chemother. 1989;23:409-415.
25. Taburet AM, Guibert J, Kitzis MD, et al. Pharmacokinetics of sodium fusidate afer single and repeated infusions and oral administration of a new formulation. J Antimicro Chemother.
1990;25(suppl B):23-31.
26. Tsuji BT, Okusanya OO, Bulitta JB, et al. Application of pharmacokinetic-pharmacodynamic modeling and the justifcation of a novel fusidic acid dosing regimen: raising Lazarus from the
dead. Clin Infect Dis. 2011;52(suppl 7): 513-519.
27. Bulitta JB, Okusanya OO, Forrest A, et al. Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. Antimicrob Agents
Chemother. 2013;57:498-507.
28. Collignon P, Turnidge J. Fusidic acid in vitro activity. Int J Antimicrob Agent 1999; 12: S45-S58.
29. Turnidge J. Fusisic acid pharmacology, pharmacokinetics and pharmacodynamics. Int J Antimicrob Agent 1999; 12: S23-S34.
30. Christiansen K. Fusidic acid adverse drug reactions. Int J Antimicrob Agent 1999; 12: S3-S9.